Theodore Robert Levin

Theodore Robert Levin

Auto-generated profile, based on publicly available information

Theodore Robert Levin

Kaiser Permanente Division of Research, Pleasanton, California, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2022 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
ASAasma Shaukat
Aasma Shaukat
TLTheodore R. Levin
Theodore R. Levin

1 November 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
TLTheodore R. Levin
Theodore R. Levin
DCDouglas A. Corley
Douglas A. Corley
CJChristopher D. Jensen
Christopher D. Jensen
JSJoanne E. Schottinger
Joanne E. Schottinger
VQVirginia P. Quinn
Virginia P. Quinn
CDChyke A. Doubeni
Chyke A. Doubeni

19 December 2006 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
TLTheodore R. Levin
Theodore R. Levin
WZWei Zhao
Wei Zhao
CCCarol Conell
Carol Conell
LSLaura C. Seeff
Laura C. Seeff
DMDiane L. Manninen
Diane L. Manninen
JSJane Schulman
Jane Schulman
Information about colonoscopy complications, particularly postpolypectomy bleeding, is limited. To quantify the magnitude and severity of colonoscopy complications. Retrospective cohort. Kaiser Permanente of Northern California. 16 318 members 40 years of age or older undergoing colonoscopy between January 1994 and July 2002. Electronic records reviewed for serious complications, including hospital admission within 30 days of colonoscopy for colonic perforation, colonic bleeding, diverticulitis, the postpolypectomy syndrome, or other serious illnesses directly related to colonoscopy. 82 serious complications occurred (5.0 per 1000 colonoscopies [95% CI, 4.0 to 6.2 per 1000 colonoscopies]). Serious complications occurred in 0.8 per 1000 colonoscopies without biopsy or polypectomy and in 7.0 per 1000 colonoscopies with biopsy or polypectomy. Perforations occurred in 0.9 per 1000 colonoscopies (CI, 0.5 to 1.5 per 1000 colonoscopies) (0.6 per 1000 without biopsy or polypectomy and 1.1 per 1000 with biopsy or polypectomy). Postbiopsy or postpolypectomy bleeding occurred in 4.8 per 1000 colonoscopies with biopsy (CI, 3.6 to 6.2 per 1000 colonoscopies). Biopsy or polypectomy was associated with an increased risk for any serious complication (rate ratio, 9.2 [CI, 2.9 to 29.0] vs. colonoscopy without biopsy). Ten deaths (1 attributable to colonoscopy) occurred within 30 days of the colonoscopy. 99.3% (16 204) of colonoscopies were nonscreening examinations. The rate of complications may be lower in a primary screening sample. The small number of observed adverse events limited power to detect risk factors for complications. Colonoscopy with biopsy or polypectomy is associated with increased risk for complications. Perforation may also occur during colonoscopies without biopsies.

27 June 2011 in Epidemiologic Reviews
Verified
Journal Article
Open access
PDF file
TLTheodore R. Levin
Theodore R. Levin
LJLaura Jamieson
Laura Jamieson
DBDaniel A. Burley
Daniel A. Burley
JRJuan Reyes
Juan Reyes
MOMichael Oehrli
Michael Oehrli
CCCindy Caldwell
Cindy Caldwell
Colorectal cancer (CRC) is an ideal target for early detection and prevention through screening. Noninvasive screening options are the guaiac fecal occult blood test and the fecal immunochemical test. Organized screening offers the promise of uniformly delivering screening to all members of a population who are eligible and due. Organized screening is defined as an explicit policy with defined age categories, method, and interval for screening in a defined target population with a defined implementation and quality assurance structure, and tracking of cancer in the population. The UK National Health Service; the Ontario, Canada Ministry of Health and Long-Term Care; and the US Veteran's Health Administration have used varied organized approaches to deliver guaiac fecal occult blood test screening to their populations. Kaiser Permanente Northern California began CRC screening in the 1960s, initially using flexible sigmoidoscopy. Implementation of organized fecal immunochemical test outreach was associated with improved Healthcare Effectiveness Data and Information Set CRC screening rates between 2005 and 2010 from 37% to 69% and from 41% to 78% in the commercial and Medicare populations, respectively. Organized fecal immunochemical test screening has been associated with an increase in annually detected CRCs, almost entirely because of increased detection of localized-stage cancers.

5 March 2013 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
CDChyke A. Doubeni
Chyke A. Doubeni
SWSheila Weinmann
Sheila Weinmann
KAKenneth Adams
Kenneth Adams
AKAruna Kamineni
Aruna Kamineni
DBDiana S.M. Buist
Diana S.M. Buist
NWNoel S. Weiss
Noel S. Weiss
Chinese translation The effectiveness of screening colonoscopy in average-risk adults is uncertain, particularly for right colon cancer. To examine the association between screening colonoscopy and risk for incident late-stage colorectal cancer (CRC). Nested case–control study. Four U.S. health plans. 1039 average-risk adults enrolled for at least 5 years in one of the health plans. Case patients were aged 55 to 85 years on their diagnosis date (reference date) of stage IIB or higher (late-stage) CRC during 2006 to 2008. One or 2 control patients were selected for each case patient, matched on birth year, sex, health plan, and prior enrollment duration. Receipt of CRC screening 3 months to 10 years before the reference date, ascertained through medical record audits. Case patients and control patients were compared on receipt of screening colonoscopy or sigmoidoscopy by using conditional logistic regression that accounted for health history, socioeconomic status, and other screening exposures. In analyses restricted to 471 eligible case patients and their 509 matched control patients, 13 case patients (2.8%) and 46 control patients (9.0%) had undergone screening colonoscopy, which corresponded to an adjusted odds ratio (AOR) of 0.29 (95% CI, 0.15 to 0.58) for any late-stage CRC, 0.36 (CI, 0.16 to 0.80) for right colon cancer, and 0.26 (CI, 0.06 to 1.11; P = 0.069) for left colon/rectum cancer. Ninety-two case patients (19.5%) and 173 control patients (34.0%) had screening sigmoidoscopy, corresponding to an AOR of 0.50 (CI, 0.36 to 0.70) overall, 0.79 (CI, 0.51 to 1.23) for right colon late-stage cancer, and 0.26 (CI, 0.14 to 0.48) for left colon cancer. The small number of screening colonoscopies affected the precision of the estimates. Screening with colonoscopy in average-risk persons was associated with reduced risk for diagnosis of incident late-stage CRC, including right-sided colon cancer. For sigmoidoscopy, this association was seen for left CRC, but the association for right colon late-stage cancer was not statistically significant. National Cancer Institute of the National Institutes of Health.

1 March 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JLJeffrey K. Lee
Jeffrey K. Lee
CJChristopher D. Jensen
Christopher D. Jensen
TLTheodore R. Levin
Theodore R. Levin
CDChyke A. Doubeni
Chyke A. Doubeni
AZAnn G. Zauber
Ann G. Zauber
DCDouglas A. Corley
Douglas A. Corley